Trials / Terminated
TerminatedNCT00430937
Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections
A Multicenter, Randomized, Assessor-Blind Study to Evaluate Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections (cSSTI)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 194 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated the efficacy and safety of daptomycin compared to vancomycin or teicoplanin for the treatment of complicated skin and soft tissue infections
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Daptomycin | 4 mg/kg intravenous once daily |
| DRUG | Vancomycin | 1 g intravenous twice daily |
| DRUG | Teicoplanin | 400 mg intravenous once daily following a loading dose of 400 mg administered at 0, 12, 24 hours on day one. |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2008-03-01
- First posted
- 2007-02-02
- Last updated
- 2012-07-16
- Results posted
- 2011-01-05
Source: ClinicalTrials.gov record NCT00430937. Inclusion in this directory is not an endorsement.